Previous close | 3.3000 |
Open | 3.3950 |
Bid | 3.1900 x 1200 |
Ask | 3.3800 x 900 |
Day's range | 3.1500 - 3.4700 |
52-week range | 2.5500 - 13.3600 |
Volume | |
Avg. volume | 81,893 |
Market cap | 10.125M |
Beta (5Y monthly) | 0.97 |
PE ratio (TTM) | N/A |
EPS (TTM) | -2.4160 |
Earnings date | 14 Nov 2022 - 18 Nov 2022 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
WOODSTOCK, Ga., June 01, 2022--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing patented Microcyn® technology-based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions and disinfectant use, and its partner, the MicroSafe Group DMCC, are pleased to announce that Nanocyn® hospital grade disinfectant has been added to the list of COVID-19 disinfectants main
WOODSTOCK, Ga., May 03, 2022--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing patented Microcyn® technology-based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, dermatological conditions and disinfectant use, and its partner, the MicroSafe Group DMCC, received EPA approval for Nanocyn® as a hospital-grade disinfectant in the United States. Nanocyn®, which is manufactured by
WOODSTOCK, Ga., March 30, 2022--Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and nasal care, and dermatological conditions, today announced that it has launched Microdox®, an urinary tract infection catheter and bladder rinse in New Zealand, Australia and South Africa.